Introduction
Candida bloodstream infections (BSIs) are frequently associated with metastatic complications [1] [2] [3] [4] and with high mortality rates, ranging from 25% to 40%. [5] [6] [7] Early differentiation between complicated and uncomplicated disease is a priority in the management of candidaemia because complicated candidaemia (C-CAN) requires longer antifungal therapy and more aggressive source control. 8, 9 Differentiation between C-CAN and uncomplicated candidaemia (UN-CAN) is usually based on the persistence of positive blood cultures (BCs) during follow-up. 8, 9 However, the sensitivity of follow-up Candida BCs is only about 50%, 10 and it further decreases when adequate antifungal therapy is started, thus making BCs a far from ideal test for monitoring complications and outcomes in patients with candidaemia. [11] [12] [13] T2Candida magnetic resonance (T2MR) is a new diagnostic method for the diagnosis of candidaemia, cleared by the US FDA 14 and by the EMA. In a recent clinical trial involving 1801 hospitalized patients, T2MR was effective in detecting the five most common species of Candida in BCs, with an overall specificity of 99.4% and sensitivity of 91.1%. 14 However, T2MR has not yet been evaluated as a follow-up test to distinguish episodes of C-CAN and UN-CAN.
The objective of this prospective multicentre study was to assess the usefulness of follow-up T2MR in comparison with BCs 
Patients and methods

Study population and setting
This prospective observational study was performed between January and June 2017 in three centres in Madrid. Patients (18 years) with BSI caused by Candida species were included in the study if they gave their informed consent and were monitored for at least 1 month or until death.
The local ethics review committees approved the study protocol, and written informed consent was obtained from each patient (ethics committee approval reference MICRO.HGUGM.2016-023).
Study design and tests performed
As soon as the first positive BC yielding Candida species was detected (index positive blood culture, Day 0), the site investigator obtained the patient's consent and managed each case according to routine clinical care, until death or hospital discharge. A transoesophageal echocardiogram and dilated ophthalmoscopy were systematically recommended at baseline for all patients included in the study. Searching for other septic metastases was performed when clinically indicated.
Blood samples were obtained at day 0, day !2, day !4, day !7 and day !14 to perform BC, T2MR and BDG, simultaneously, until all tests were negative. In all hospitals, only the results of the BC were available to clinicians. Both T2MR and BDG results were provided at the end of the study and had no influence on the clinical management of the patients.
Microbiological samples
BCs were obtained through venepuncture using standard procedures and processed in the clinical laboratories with the BD Bactec FX (Becton, Dickinson, Sparks, MD, USA) at Hospital Gregorio Marañón and Hospital Ramon y Cajal and with the BacT/Alert 3D (Biomerieux) at Hospital 12 de Octubre. T2MR and the BDG assay were processed twice weekly at the clinical laboratory of the coordinating centre (Hospital General Gregorio Marañón). The T2MR (T2 Biosystems Inc.) was performed in EDTA wholeblood samples obtained from a peripheral vein and processed automatically following all the steps previously described by Mylonakis et al.
14
T2MR results were grouped based on antifungal resistance patterns of different Candida species, 8 and reported as follows: C. albicans/C. tropicalis, C. krusei/C. glabrata and C. parapsilosis. If the internal control was invalid and there were no positive T2MR signals, an 'invalid' result was displayed, indicating that the specimen may contain inhibitors that interfered with Candida detection.
14 Serological detection of BDG was performed using the Fungitell assay kit (Associates of Cape Cod) according to the manufacturer's instructions, using a cut-off of 80 pg/mL. Results were read and analysed with a BioTek ELX808TM Microplate Reader and GEN5 Software (BioTek U.S., VT, USA) and considered positive when the values were 80 pg/mL. 15 
Clinical data
The following data were prospectively collected using a standardized case report form: age; sex; underlying disease; Charlson's comorbidity index; risk factors for candidaemia (i.e. presence of central venous catheter, parenteral nutrition, corticosteroid therapy, recent surgery, previous Candida colonization); clinical presentation; source of fungaemia; Candida species; type of antifungal therapy and dosage; presence of septic metastasis; source control of infection; and clinical evolution of the patient.
Definition of C-CAN
C-CAN was defined as all the episodes involving metastatic spread to other organs (i.e. endocarditis, other endovascular infections, ocular candidiasis, etc.), and/or with attributable mortality during the follow-up period.
Other definitions
An episode of candidaemia was defined as a patient that had at least one peripheral blood culture positive for Candida species. As for the underlying diseases, we classified patient situations as rapidly fatal, ultimately fatal or non-fatal according to the classic criteria of McCabe and Jackson. 16 Sepsis, septic shock and Pitt's bacteraemia score were defined according to standard international criteria. 17, 18 As for the source of infection, an episode of candidaemia was considered as catheter-related if: (i) the catheter tip culture was positive for the same Candida species; (ii) there was evidence of catheter exit site exudate with the same Candida species; or (iii) the differential time to positivity of BCs obtained from the catheter and peripheral veins was 2 h. 19 The urinary tract was considered to be the portal of entry in patients with urological predisposing conditions (i.e. manipulation or obstruction of the urinary tract) and evidence of urinary tract infection caused by the same species of Candida.
The abdomen was considered to be the origin of the candidaemia when a patient had evidence of abdominal infection and (i) a positive culture from the intra-abdominal space was obtained during surgery or by needle aspiration, and/or (ii) no other apparent sources of candidaemia were detected. When a source of candidaemia could not be identified, candidaemia was defined as 'primary'.
Patients were considered to have Candida septic metastasis when an infection due to the same Candida species occurred in a site that was distant from the source of the candidaemia. In cases in which no culture was available, the distant infection had to be temporally related to the fungaemia and with no alternative cause explaining the clinical condition.
Infective endocarditis was diagnosed according to Duke criteria; 20 ocular candidiasis was classified based on previous criteria; 1, 4 and septic thrombophlebitis required the presence of venous thrombosis, confirmed by imaging techniques, in the setting of persistent candidaemia. 19 Mortality was considered attributable to candidaemia in patients who died with persistent positive BCs for Candida species or with persistent signs or symptoms of candidaemia. Doubtful cases were independently reviewed by three investigators blind to T2MR and BDG results (A. V., M. M. and P. M.); unanimous agreement was required.
Statistical analysis
Sensitivity, specificity and predictive values were calculated for predicting C-CAN for (i) BCs, (ii) T2MR and (iii) BDG at different times [from Day 0 to Day 5 (early period) and beyond Day 5 (late period)]. The timeframes were chosen because they represent the period in which follow-up BCs are usually performed in real clinical practice. Non-normally distributed continuous variables were compared using the t-test, and normally distributed variables were compared using the t-test or analysis of variance. Stepwise logistic regression models were applied in the multivariate analysis to control for potential confounders and for risk factors of C-CAN. Variables with a P value ,0.1 in the univariate analysis were included in the multivariate models. Differences were considered to be significant for P , 0.05. The analysis was carried out with SPSS 18.
Results
During the study period, 44 patients were diagnosed with an episode of candidaemia in the three institutions. Of these, six patients died within the first 2 days, five did not consent to participate in the Muñoz et al. iv14 study and three had invalid T2MR results (one patient from each participating hospital).
Thus, 30 patients were included in the final analysis and are the object of the present study. The main pathogens were Candida albicans, Candida parapsilosis, Candida glabrata and Candida tropicalis, which were isolated in 43.3%, 30.0%, 16.7%, and 6.7% of patients, respectively. Fundoscopies and echocardiograms were performed in 86.7% and 80% of patients, respectively.
Clinical characteristics of complicated and uncomplicated Candida BSI
Nine out of the 30 patients (30.0%) fulfilled the criteria for C-CAN whereas 21 (70.0%) were classified as having uncomplicated disease. Clinical characteristics of the nine patients with C-CAN are shown in Table 1 . The most frequent complications were ocular candidiasis in 5/9 (55.6%) and infective endocarditis in 2/9 patients (22.2%).
The main epidemiological characteristics and clinical manifestations in UN-CAN and C-CAN are compared in Table 2 . Age, sex, underlying disease, risk factors for candidaemia, BSI source and aetiology were similar between groups. However, patients with complicated disease were more likely to have sepsis at the time of Candida BSI (55.6% versus 9.5%, P " 0.01). No further differences were found regarding Pitt score, adequate source control of infection, length of hospital stay and in-hospital mortality.
Positivity rates for BCs, T2MR and b-D-glucan
The median time of appropriate antifungal treatment before obtaining the first blood sample processed for follow-up BC, T2MR and BDG was 2 days, with no differences between UN-CAN and C-CAN (2 versus 3 days, P " 0.44).
Overall, 116 follow-up T2MR samples, 111 BDG samples and 69 BC sets were collected during the study period. Of these, 82 T2MR, 80 BDG and 58 BCs, respectively, were collected during the first Beyond day 5 (late period), the positivity rates of the three studied tests were 7/34 (20.6%), 3/11 (27.3%) and 26/31 (83.9%). There were eight invalid T2MR results (6.9%).
During the early period, follow-up evaluation with BCs, T2MR and BDG showed that all tests were already negative in 6/30 patients (20%), whereas they were all positive in 6/30 (20%) patients. Discordant results were obtained for the remaining 18/30 (60%) patients. In most cases, discordant results consisted either of a positive T2MR and BDG assay with negative BCs (7/30, 23.3%) or a positive BDG assay with negative T2MR and BCs (7/30, 23.3%). Muñoz et al.
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The diagnostic value of the early BCs, T2MR and BDG for predicting C-CAN are shown in Table 3 . Patients with a C-CAN were more likely to have a positive T2MR, both in the early [5/21 (23.8%) versus 9/9 (100%), P 0.001] and in the late period [1/19 (5.3%) versus 6/7 (85.7%), P " 0.001]. Neither BCs nor BDG could differentiate episodes of C-CAN and UN-CAN during the early period. Table 3 also shows the sensitivity, specificity and predictive values of all three techniques for predicting C-CAN. In the early period, T2MR showed a higher sensitivity than BCs for predicting C-CAN, and both had similar specificities. In the late period, the T2MR continued to remain positive longer than BC, but not as long as the BDG assay. However, in the late period BDG showed a very low specificity (33.3%).
A logistic regression model was constructed to evaluate independent predictors for C-CAN (Table 4) . After adjusting for age, sex and severity of disease the only factor that remained significantly and independently associated with the development of complicated disease was a positive T2MR during the early period (OR 36.5; 95% CI 1.7-779.2). The Hosmer-Lemeshow goodnessof-fit test results indicate that the C-CAN model accurately reflected the data (P " 0.02).
Discussion
To our knowledge, this is the first report demonstrating that T2MR could potentially be used to monitor episodes of Candida BSI to predict outcomes. Compared with the traditional BCs and BDG assay, T2MR proved to be the most effective method to recognize episodes of C-CAN in the early follow-up period, while being faster and easier to use.
Rapid diagnosis of metastatic complications is a challenging area for candidaemia management. 8, 9 Several factors have been related to early development of complications in patients with candidaemia, including C. albicans fungaemia, 1, 21, 22 need for haemodialysis after candidaemia, 4 and above all the persistence of positive BCs during the follow-up period. 3, 4, 21, 23, 24 However, BCs have a low sensitivity for Candida species 10 and are strongly influenced by antifungal therapy, thus further impairing their ability to identify patients with C-CAN. In the present study, only 4/9 (44.4%) patients with C-CAN had positive follow-up BCs. Therefore, new diagnostic methods that provide rapid and sensitive results for predicting complicated episodes of candidaemia are needed.
T2MR is a new nano-diagnostic, fully automated technology that can directly and accurately detect molecular targets of Candida species within whole blood specimens, without the need for prior isolation. 25 This new technique has been studied and has demonstrated promising results for the diagnosis of candidaemia; 14 however, to date, no reports have evaluated its role as a tool for early detection of complications in patients with previously diagnosed candidaemia.
The findings of our study indicate that in comparison with BCs or the BDG assay, the performance of a follow-up T2MR in patients with a proven diagnosis of candidaemia could better predict which patients have C-CAN or poor related prognosis, even if follow-up BCs are negative. In fact, a positive T2MR result performed within the first 5 days after the positivity of the index BC identifies a subgroup of patients with an almost 30-fold increase in the probability of developing a complication related to candidaemia. Moreover, T2MR for diagnosis of complicated candidaemia JAC iv17 although the sensitivity was similar to that of BDG, the specificity of T2MR was about twice that of BDG, thus confirming the high rates of false-positive BDG results in high-risk populations. 10 We believe that our results represent a significant step forward in the better management of candidaemia. Follow-up T2MR could be useful to anticipate episodes of C-CAN and, due to its ideal time to result, 14 the results could be available early enough that diagnostic and management strategies could potentially modify patient outcomes. This is particularly true for patients with C-CAN, where early timing remains a concern.
Although not directly evaluated in this study, the systematic use of T2MR during follow-up of candidaemic patients could help clinicians to intervene early, and therefore improve the outcomes for patients with complicated disease. Early detection of a deepseated candidiasis or of a metastatic complication could significantly change the clinical management of these patients. For example, an urgent source control of infection could be needed (especially in patients with infective endocarditis) or the selection of antifungal therapy and dosage could be influenced (switch to liposomal amphotericin B or fluconazole in case of ocular candidiasis or higher echinocandin dosage in case of infective endocarditis). Finally, since a positive T2MR during follow-up was associated with a worse outcome, the decision regarding the admission ward (ICU versus medical or surgical ward) could be modified.
This study has some limitations that should be assessed. First, our study conclusions are limited by the relatively small number of patients. Second, although a systematic search for metastatic complications was recommended in all patients, only 24/30 (80%) patients had an echocardiogram performed, although in most cases other complications were investigated according to clinical conditions. Third, long-term outcome was not assessed and as the study was a proof of concept T2MR results were not available for clinicians, so we could not examine whether T2MR information would have changed patient management or outcomes. Strengths of our study include the fact that it was a prospective study performed in three large hospitals and that it represents important real-life experience with T2MR in candidaemic patients.
In conclusion, we found that a positive T2MR test performed in patients with proven candidaemia may be a better marker of complicated infection than follow-up BC or the BDG assay. Given the difficulties in daily clinical practice of detecting episodes of C-CAN, our results support the use of T2MR as a follow-up test in patients with candidaemia, as well as the need for future research on its influence on duration of therapy and the type of antifungals in candidaemia management.
